Does Rallies show Form 4 insider transactions for CGON?

Yes. Rallies tracks CGON insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is CGON research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CGON. It does not provide personalized investment advice.

CGON (CG Oncology, Inc. Common stock) Stock Analysis - Insider Trades

CG Oncology, Inc. Common stock (CGON) is a publicly traded Healthcare sector company. As of May 20, 2026, CGON trades at $64.79 with a market cap of $5.55B and a P/E ratio of -27.62. CGON moved +2.37% today. Year to date, CGON is +61.74%; over the trailing twelve months it is +143.82%. Its 52-week range spans $14.80 to $75.50. Analyst consensus is strong buy with an average price target of $89.47. Rallies surfaces CGON's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading CGON stock inside the company?

Recent CGON insider activity includes Mulay James sold 15.60K, Mulay James sold 654, Mulay James sold 1.31K, Mulay James sold 654, and Mulay James sold 10.49K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

CGON Key Metrics

Key financial metrics for CGON
Metric	Value
Price	$64.79
Market Cap	$5.55B
P/E Ratio	-27.62
EPS	$-2.33
Dividend Yield	0.00%
52-Week High	$75.50
52-Week Low	$14.80
Volume	666.18K
Avg Volume	0
Revenue (TTM)	$5.07M
Net Income	$-186.75M
Gross Margin	0.00%

Recent CGON Insider Trades

Mulay James sold 15.60K (~$1.14M) on Apr 17, 2026.
Mulay James sold 654 (~$41.53K) on Mar 16, 2026.
Mulay James sold 1.31K (~$83.19K) on Mar 16, 2026.
Mulay James sold 654 (~$28.88K) on Jan 9, 2026.
Mulay James sold 10.49K (~$555.92K) on Jan 9, 2026.

Latest CGON News

CG Oncology rises as traders price in near-term Phase 3 PIVOT-006 data and target hikes — Apr 30, 2026
CG Oncology dips as insider-sale filings hit tape after recent rally — Apr 22, 2026
CG Oncology rises as accelerated Phase 3 PIVOT-006 readout outlook supports shares — Apr 21, 2026
CG Oncology slips as investors de-risk ahead of May 7 earnings catalyst — Apr 20, 2026
CG Oncology jumps as PIVOT-006 Phase 3 catalyst nears and analysts turn louder — Apr 19, 2026

CGON Analyst Consensus

13 analysts cover CGON: 0 strong buy, 13 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $89.47.

Common questions about CGON

Who is trading CGON stock inside the company?: Recent CGON insider activity includes Mulay James sold 15.60K, Mulay James sold 654, Mulay James sold 1.31K, Mulay James sold 654, and Mulay James sold 10.49K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for CGON?: Yes. Rallies tracks CGON insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is CGON research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CGON. It does not provide personalized investment advice.